| SC 13D/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | Lyra Therapeutics, Inc. | 12,757,563 | 24.3% | EDGAR |
| SC 13G/A | 2024-02-14 | Point72 Asset Management, L.P. | Lyra Therapeutics, Inc. | 3,000,000 | 5.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Nantahala Capital Management, LLC | Lyra Therapeutics, Inc. | 4,752,324 | 8.9% | EDGAR |
| SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | Lyra Therapeutics, Inc. | - | 7.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners II, L.P. | Lyra Therapeutics, Inc. | 5,553,552 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | PURA VIDA INVESTMENTS, LLC | Lyra Therapeutics, Inc. | 1,613,844 | 3.1% | EDGAR |
| SC 13G | 2024-02-13 | Vestal Point Capital, LP | Lyra Therapeutics, Inc. | 3,000,000 | 5.7% | EDGAR |
| SC 13G | 2023-11-16 | Point72 Asset Management, L.P. | Lyra Therapeutics, Inc. | 3,000,000 | 5.4% | EDGAR |
| SC 13G | 2023-08-25 | Samsara BioCapital, L.P. | Lyra Therapeutics, Inc. | 2,780,261 | 5.6% | EDGAR |
| SC 13G | 2023-06-12 | CITADEL ADVISORS LLC | Lyra Therapeutics, Inc. | - | 5.8% | EDGAR |
| SC 13D/A | 2023-06-09 | NBVM GP, LLC | Lyra Therapeutics, Inc. | 5,888,416 | 11.9% | EDGAR |
| SC 13D/A | 2023-06-02 | PERCEPTIVE ADVISORS LLC | Lyra Therapeutics, Inc. | 12,757,563 | 25.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Venrock Healthcare Capital Partners II, L.P. | Lyra Therapeutics, Inc. | 3,433,268 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | PURA VIDA INVESTMENTS, LLC | Lyra Therapeutics, Inc. | 2,157,298 | 6.8% | EDGAR |
| SC 13G | 2023-02-14 | Nantahala Capital Management, LLC | Lyra Therapeutics, Inc. | 2,220,830 | 7.0% | EDGAR |
| SC 13G/A | 2023-02-13 | INTERSOUTH PARTNERS VII L P | Lyra Therapeutics, Inc. | 738,203 | 2.3% | EDGAR |
| SC 13G/A | 2023-02-07 | Polaris Venture Partners V, L.P. | Lyra Therapeutics, Inc. | 1,062,259 | 3.3% | EDGAR |
| SC 13G | 2022-11-08 | PURA VIDA INVESTMENTS, LLC | Lyra Therapeutics, Inc. | 2,782,091 | 8.7% | EDGAR |
| SC 13D/A | 2022-04-22 | NBVM GP, LLC | Lyra Therapeutics, Inc. | 4,083,000 | 12.8% | EDGAR |
| SC 13G | 2022-04-22 | Venrock Healthcare Capital Partners II, L.P. | Lyra Therapeutics, Inc. | 3,433,050 | 10.0% | EDGAR |